We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Polarean Imaging Plc | POLX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 3.70% | 1.40 | 15:27:18 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.35 | 1.35 | 1.40 | 1.40 | 1.35 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 03/6/2025 09:35 by washingmachine I’m having a incredible dayIn fact I’m thinking the best for 2 years ITM BLU SCE all risen for over 3 days. I’ve had to laugh at Justin Waite The biggest ramper of this stock a couple of years ago , it was endless Yesterday he did a podcast Apparently POLX are out of favour bla bla bla and all he could focus on was loss making needing money He really talks and listens to his own tripe Pretty embarrassing when you have the leading technology in this space And are so involved with Philips Never mind what’s coming.. Which I’m very confident about This will trade at 8 pence plus by Xmas |
Posted at 02/6/2025 07:31 by washingmachine Oh dear moon , one day u will have gained enough experience to not post such irrelevance ! For holders. This will open POLX to a huge market opportunity Don't be surprised if this is what Philips are waiting for to make a move .... Or any one of several tier 1 s in this space. |
Posted at 02/6/2025 07:24 by moontheloon Regardless of news like this the main thing is last holders towards autumn left holding the baby are going to have their investment diluted by 50%Why don't Phillips,just buy polx... why don't they?? |
Posted at 02/6/2025 07:01 by bagpuss67 Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that the US Food and Drug Administration ("FDA") has approved the Company's Supplemental New Drug Application ("NDA") to expand the indication of XENOVIEW®. This approval immediately lowers the minimum patient age from 12 to six years old, significantly broadening access to this technology and expanding Polarean's total addressable market.The approval means that XENOVIEW can now be used with MRI for evaluation of lung ventilation in adults and paediatric patients aged six years and older, representing an increase in the number of eligible patients by approximately one million. The FDA supplement approval also includes the introduction of new XENOVIEW Dose Delivery Bag sizes tailored for smaller lungs of younger patients and corresponding updates to the HPX Polarisation Measurement Station to measure various bag sizes. This approval reinforces Polarean's dedication to advancing functional lung imaging and increasing access to its technology, enabling enhanced care for a broader patient population. |
Posted at 15/5/2025 13:33 by moontheloon Great exposure but not rns worthy, as we've been there done that. . Rns if they pay polx $1m |
Posted at 14/5/2025 14:45 by moontheloon Maybe Phillips are buying polx. Always been a potential |
Posted at 04/4/2025 21:57 by moontheloon Zak mir rarely says anything positive about polx. Polarean Imaging (POLX), a commercial-stage medical imaging technology leader in advanced MRI of lung function, provides a full year unaudited trading update for the year ended 31 December 2024 and a commercial update. The Company expects to report FY24 unaudited revenue of between US$3.0 million and $3.1 million (audited 2023: $891k), exceeding the upper end of revenue guidance of US$2.5 million to US$3.0 million.Comment: Just when it appeared that POLX was down and out, it has become an interesting recovery situation, one that could rebound all the more given that most in the market have probably been wrong footed by the turnaround. |
Posted at 15/11/2024 10:20 by m_night10 You waste your time and life moon. A few buys like the 740k you see now and it will go to 2p and then over with news faster than you can blink. :)POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 14/11/2024 09:11 by m_night10 POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 08:36 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
